These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24118072)

  • 1. Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors.
    Qiu LP; Chen L; Chen KP
    Fundam Clin Pharmacol; 2014 Aug; 28(4):364-81. PubMed ID: 24118072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of chronic hepatitis B infection.
    Sundaram V; Kowdley K
    BMJ; 2015 Oct; 351():h4263. PubMed ID: 26491030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG; Mohammed R; Yuen MF; Kao JH
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives.
    Sun D; Zhu L; Yao D; Chen L; Fu L; Ouyang L
    Eur J Med Chem; 2018 Mar; 147():205-217. PubMed ID: 29438889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HBV agents derived from botanical origin.
    Qiu LP; Chen KP
    Fitoterapia; 2013 Jan; 84():140-57. PubMed ID: 23164603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.
    Okada M; Enomoto M; Kawada N; Nguyen MH
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy.
    Tawada A; Kanda T; Imazeki F; Yokosuka O
    Hepatol Int; 2016 Jul; 10(4):574-93. PubMed ID: 27026375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in antivirals against hepatitis B virus.
    Wang YJ; Yang L; Zuo JP
    Virus Res; 2016 Feb; 213():205-213. PubMed ID: 26732483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
    Chien RN; Liaw YF
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1081-92. PubMed ID: 19187868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
    Abu-Amara M; Feld JJ
    Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B.
    Xu XW; Chen YG
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):350-9. PubMed ID: 16911930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
    Singal AK; Fontana RJ
    Aliment Pharmacol Ther; 2012 Mar; 35(6):674-89. PubMed ID: 22257108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
    Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
    J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.